Esophageal Cancer, Esophageal Neoplasms
Conditions
Keywords
response, neoadjuvant, PET/MRI, radiomics, GEJ cancer
Brief summary
Evaluate the potential role of PET/MRI as a predictor of esophageal and junctional cancers in response to neoadjuvant chemoradiotherapy (nCRT).
Detailed description
This is a prospective, observational single center study which plans to enroll patients with biopsy proven potentially resectable esophageal or junctional cancer scheduled to receive nCRT (CROSS regimen) prior to surgery. The study aims to evaluate Routine pre-treatment work-up includes PET to stage the tumour extension. * PET/MRI (Magnetic resonance imaging) will replace the PET component of CT(computed tomography) * An additional intermediate 18-FDG (Fluorodeoxyglucose) PET/MRI will be performed during nCRT * Post nCRT imaging, as required prior to surgery, will be PET/MRI six weeks after treatment completion. * 8-12 weeks post nCRT completion surgery will be performed, based on each patient's performance status and response to nCRT * Histopathological samples of the excised tumor and lymph nodes will be used for diagnosis, staging and description of qualitative and quantitative parameters Routine clinical and radiological follow-up for 24 months (for the scope of this study) will follow the standard clinical workflow assigned to this group of patients.
Interventions
OTHERhybrid PET/MRI
An additional intermediate 18-FDG PET/MRI will be performed during neoadjuvant chemo-radiation therapy. Routine pre-treatment work-up PET/MRI will replace PET alone.
Sponsors
IRCCS San Raffaele
Associazione Italiana per la Ricerca sul Cancro
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* biopsy-proven esophageal or junctional carcinomas (either adenocarcinoma (AC) or squamous cell carcinoma (SCC) for which an Ivor-Lewis transthoracic esophagectomy with supramesocolic and mediastinal lymphadenectomy is indicated; * visible tumor on pre-treatment imaging; * ≥ 18 years of age; * signed informed consent.
Exclusion criteria
* \- incomplete preoperative imaging assessment; * contraindications to neoadjuvant treatment; * contraindications to preoperative imaging (such as pacemaker, allergy to contrast agents); * inability to complete imaging examinations (i.e. severe claustrophobia); * contraindication to surgery (comorbidities, distant metastatic disease (imaging confirmed)); * pregnant or lactating women * severe hypersensitivity to gadobutrol or fludeoxyglucose F18.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response to neoadjuvant treatment -MRI | 0-36 months | MRI component including Dynamic Contrast Enhanced (DCE); quantitative evaluation and delta between timepoints |
| Response to neoadjuvant treatment -PET | 0-36 months | PET component -quantitative evaluation and delta between timepoints |
| Response to neoadjuvant treatment - Histology | 0-36 months | Evaluate degree of tumor regression after neoadjuvant therapy according to the Mandard Tumour regression grade ; integrated Immunohistochemistry |
| Response to neoadjuvant treatment -Radiomics | 0-36 months | Radiomic features extracted from hybrid imaging |
| Imaging parameters as potential predictors of tumor response | 0- 48 months | Select imaging parameters that can be considered potential predictors of the responder/non-responder status assessment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Early regression model (ERI) | 0- 60 months | Evaluate the ERI model as a predictor of histological response (TRG grade) based on MRI tumor volume assessment |
Countries
Italy
Contacts
PRINCIPAL_INVESTIGATORFrancesco De Cobelli, MD
IRCCS Ospedale San Raffaele
Outcome results
None listed